問卷

TPIDB > Principal Investigator

Principal Investigator


Taipei WanFang Hospital (Managed by Taipei Medical Univeristy) (在職)

Division of Infectious Disease

Division of General Internal Medicine

Division of Infectious Disease

更新時間:2023-09-19

歐聰億Ou, Tsong-Yih
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

篩選

List

25Cases

2015-04-01 - 2016-06-30

Phase I/II

A Phase I/II, Prospective, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of an Inactivated Cell Culture Derived H7N9 Influenza Vaccine in Healthy Adult Subjects
  • Condition/Disease

    H7N9 Influenza Vaccine

  • Test Drug

    AT-501

Participate Sites
3Sites

Terminated3Sites

2018-10-15 - 2019-11-30

Phase III

A Phase III, Prospective, Randomized, Open-Labeled, Active-Controlled, Multi-Center Study to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine, GC FLU, in Adults Aged 20 to 50
  • Condition/Disease

    Influenza

  • Test Drug

    GCFLU Quadrivalent Pre-filled Syringe inj.

Participate Sites
4Sites

Terminated4Sites

2015-09-01 - 2017-12-31

Phase III

A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Moxifloxacin IV/PO for Treating Adult Subjects with Community-Acquired Bacterial Pneumonia (CABP)
  • Condition/Disease

    The initial targeted indications are serious skin infections (ABSSSI), community acquired lower respiratory tract infections (CABP) and urinary tract infections

  • Test Drug

    Omadacycline (PTK 0796)

Participate Sites
5Sites

Terminated5Sites

2014-02-07 - 2015-07-30

Phase II/III

A Phase 3, multicenter, randomized, double-blind, active controlled study to evaluate the efficacy and safety of IV and oral delafloxacin compared with vancomycin + aztreonam in patients with acute bacterial skin and skin structure infections
  • Condition/Disease

    acute bacterial skin and skin structure infections

  • Test Drug

    Delafloxacin

Participate Sites
7Sites

Terminated7Sites

2021-07-21 - 2023-03-29

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2008-09-01 - 2009-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Terminated14Sites

1 2 3